(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(amc 2024-05-07)
Expected move: +/- 9.03%
7.32% $ 3.52
@ $2.70
Emitido: 14 feb 2024 @ 09:30
Retorno: 30.37%
Señal anterior: feb 12 - 12:17
Señal anterior:
Retorno: -2.17 %
Live Chart Being Loaded With Signals
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally...
Stats | |
---|---|
Volumen de hoy | 1.70M |
Volumen promedio | 2.86M |
Capitalización de mercado | 299.90M |
EPS | $0 ( 2024-03-05 ) |
Próxima fecha de ganancias | ( $-0.0900 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -27.08 |
ATR14 | $0.00900 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Jenkins Abigail L. | Sell | 0 | Common Stock |
2024-03-15 | Schobel Alexander Mark | Sell | 50 000 | Common Stock |
2024-03-09 | Barber Daniel | Sell | 37 938 | Common Stock |
2024-03-09 | Boyd Peter E. | Sell | 8 370 | Common Stock |
2024-03-09 | Braender Lori J | Sell | 10 530 | Common Stock |
INSIDER POWER |
---|
89.70 |
Last 98 transactions |
Buy: 6 495 786 | Sell: 225 172 |
Volumen Correlación
Aquestive Therapeutics Correlación
10 Correlaciones Más Positivas | |
---|---|
MDLZ | 0.94 |
MMSI | 0.939 |
CWST | 0.938 |
VTYX | 0.931 |
MTRY | 0.93 |
OSIS | 0.928 |
CFIV | 0.928 |
IOVA | 0.926 |
HBIO | 0.925 |
QRTEP | 0.925 |
10 Correlaciones Más Negativas | |
---|---|
OBT | -0.951 |
HONE | -0.948 |
GBNY | -0.946 |
FRAF | -0.943 |
PFC | -0.943 |
WNEB | -0.942 |
COFS | -0.941 |
AUB | -0.941 |
PNBK | -0.934 |
FUNC | -0.931 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aquestive Therapeutics Correlación - Moneda/Commodity
Aquestive Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $50.58M |
Beneficio Bruto: | $29.97M (59.25 %) |
EPS: | $-0.130 |
FY | 2023 |
Ingresos: | $50.58M |
Beneficio Bruto: | $29.97M (59.25 %) |
EPS: | $-0.130 |
FY | 2022 |
Ingresos: | $47.68M |
Beneficio Bruto: | $28.29M (59.34 %) |
EPS: | $-1.240 |
FY | 2021 |
Ingresos: | $50.83M |
Beneficio Bruto: | $50.83M (100.00 %) |
EPS: | $-2.10 |
Financial Reports:
No articles found.
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico